most common causes of death are myocardial infarction and cancer at a median age of 54 years [Huang et al., 2006; Goto et al., 2013] . The Japanese Werner Consortium, Chiba University, in Chiba, Japan, proposed diagnostic criteria consisting of 6 cardinal symptoms: progeroid change of hair, cataracts, changes of skin including intractable skin ulcer, soft-tissue calcification, and a birdlike abnormal face [Takemoto et al., 2013] .
The WRN gene encodes a nuclear DNA helicase with exonuclease activity which participates in DNA repair during various DNA transactions [Croteau et al., 2014; Shamanna et al., 2017] . More than 80 different WRN pathogenic variants have been reported from all over the world [Huang et al., 2006; Yokote et al., 2017] . Due to the presence of founder mutations, Japan and the region of Sardinia in Italy are among countries with the highest frequencies of WS [Satoh et al., 1999; Masala et al., 2007; Goto et al., 2013] . Another potential founder mutation has been reported in India/Pakistani patients, although WS may be underdiagnosed due to the relatively low awareness of this disorder [Saha et al., 2013] . A recent report showed that the increase of compound heterozygotes and decrease of homozygotes among those cases referred to the Japanese Werner patients likely reflects the social trend of a decrease in consanguineous marriages [Yamaga et al., 2017] . Here, we report the results of mutation analyses of WRN loci in 4 newly identified WS patients referred to the Japanese Werner Consortium. All 4 patients were compound heterozygotes of the Japanese founder mutation and the other pathological variant, 3 of which have not been described previously.
Materials and Methods

Patient Recruitment
Japanese WS patients were anonymously referred to the Japanese Werner Consortium by physicians who requested a molecular confirmation of a WRN mutation. Consent forms obtained by the physicians follow local regulations. After enrollment, blood samples collected from the patients were shipped to us for genetic testing.
Genetic Analysis
Blood samples were processed as described previously [Huang et al., 2006] . Genomic DNA was subjected to Sanger sequencing of 36 WRN exons as described before.
For the phase study of a compound heterozygote, the region of intron 25-26 of the WRN gene was amplified from the patient's DNA. The PCR product was then subcloned into pBlueScriptII-KS linearized with XhoI and HindIII using the Gibson assembly system according to the manufacturer's instruction (New England Biolabs, Cata#E2611) [Gibson et al., 2009] . Primers used for the amplification of WRN exon 26 for Gibson assembly were: I25-F: ACGACTCACTATAGGGCGAATTGGAGCTC GGTAAACAG-TGTAGGAGTCTG ; I26-R: CCTCGAGGTCGACGGTATCGA-T AAGCTT CTTG TGAGAGGCCTATAAACT . The underlines indicate the sequences in the WRN gene, and the regions without underlines are the sequence of pBlueScript linearized with XhoI and HindIII. The assembled DNA was used for Escherichia coli transformation, and the plamids isolated from 8 bacterial colonies were analyzed by Sanger sequencing.
Results
The first case is a 62-year-old Japanese woman. Her medical history included bilateral cataract at 42 years of age, diabetes mellitus at age 53, and calcification in the left Achilles tendon at age 55. She subsequently developed a refractory skin ulcer and underwent left leg amputation. At her first visit to our hospital, she exhibited short statue, a high-pitched voice, a bird-like facial appearance, thin extremities, and refractory skin ulcers on her right foot. Her height was 1.46 m, weight was 35.2 kg, and her BMI was 14.4 kg/m 2 . Her diabetes was controlled by intensive insulin therapy, the HbA1c was maintained less than 7.0%. X-ray examination revealed massive calcification in the right Achilles tendon, which is highly characteristic of WS [Takemoto et al., 2013] , and ultrasound demonstrated 1.6 mm atherosclerotic plaque in the left carotid artery ( Fig. 1 ) .
Sanger sequencing of WRN exons in the abovementioned case revealed a novel heterozygous variant, c.1587G>A, p.Trp529 * in exon 13, and a heterozygous Japanese founder mutation, c.3139-1G>C, which results in the deletion of exon 26 (r.3139_3233del95) followed by the premature termination, p.Gly1047Phefs * 14 ( Fig. 2 ) . The second case was referred to us with a clinical diagnosis of WS, and the sequencing analysis showed a heterozygous Japanese founder mutation and a novel heterozygous variant, c.2448+1G>A, which results in the skipping of exon 20 (r.2274_2448del175) followed by the premature termination, p.Ser759Valfs * 3 ( Fig. 2 ) .
The third case was referred to us with a clinical diagnosis of WS, presenting with all 6 cardinal symptoms of the syndrome proposed by the Japanese Werner Consortium. This patient carried a heterozygous Japanese founder mutation and a compound missense variant, c.1720G>A, p.Gly574Arg. The p.Gly574Arg was previously reported in a single German patient as a compound heterozygous mutation [Tadokoro et al., 2013; Yokote et al., 2017] . Although biochemical studies had already demonstrated the abrogation of enzymatic activities in a recombinant WRN protein with p.Gly574Arg [Tadokoro et al., 2013] , the identification of the second p.Gly574Arg case further strengthens the notion of the pathogenicity of this variant and the loss of enzymatic activity as the cause of the WRN mutation.
The fourth case also presented with classical features of WS and was referred to us for genetic testing. This pa- 217 tient carried a heterozygous Japanese founder mutation, c.3139-1G>C, and a novel heterozygous variant, c.3233+1G>T ( Fig. 3 ) . The c.3139-1G>C is located at 5 ′ of exon 26, and c.3233+1G>T is located at 3 ′ of exon 26, both are expected to cause a deletion of exon 26. Parental samples were unable to be obtained to determine the phase of 2 pathogenic variants. We therefore opted to separate 2 alleles by PCR subcloning using Gibson assembly. Following the bacterial transformation and plasmid isolation, 4 out of 8 clones had the c.3139-1G>C change, but not c.3233+1G>T (allele 1 in Fig. 3 ) ; 3 out of 8 clones had c.3233+1G>T, but not c.3139-1G>C (allele 2 in Fig. 3 ) , and 1 did not have the insert, roughly falling into the expected 1: 1 ratio of 2 alleles. This confirms the compound heterozygous status of WRN mutations in this patient.
Discussion
We described 3 newly identified null WRN pathogenic variants and a previously reported amino acid substitution variant found in Japanese WS patients. All were found as one of the compound heterozygous changes in combination with the Japanese founder mutation. It has been noted that the proportion of compound heterozygotes increased from 14.2% in 1997 to 31.8% in 2017 in Japanese WS patients. Reciprocally, the homozygotes of the Japanese founder mutation decreased from 73.2 to 63.6% during the same 20-year period [Yamaga et al., 2017] . Considering the trend in Japan to fewer consanguineous marriages, an increase in compound heterozygotes and corresponding decrease in homozygotes is to be expected [Nalls et al., 2009] .
Most of the pathogenic variants of the WRN gene were null mutations, either splicing, stop codon, or small indels [Yokote et al., 2017] . Amino acid substations within the exonuclease domain found in a German patient causes protein instability [Huang et al., 2006] ; thus, they were also functionally null. There have been only 2 likely pathogenic missense variants, namely p.Arg637>Trp and p.Gly574Arg [Uhrhammer et al., 2006; Tadokoro et al., 2013; Yokote et al., 2017] , both of which were found in the compound heterozygotes with null mutations. Of those, only p.Gly574Arg was pathogenic [Tadokoro et al., 2013] . Our patient with p.Gly574Arg had all 6 cardinal symptoms, indicating that the combination with a null mutation is sufficient to develop typical WS features.
When a patient presents with classical features of WS, the presence of 2 heterozygous WRN mutations is generally considered sufficient to make a diagnosis of WS. We, however, felt it is necessary to determine the phase of 2 heterozygous mutations, c.3233+1G>T and c.3139-1G>C, because both of them result in the skipping of exon 26. Strictly speaking, this should be done for all compound heterozygotes when technically feasible. In fact, recommendation of the description of sequence variation (www.hgvs.org/mutnomen/recs-DNA.html#DNA) clearly distinguishes compound heterozygosity with known phases, e.g., c.
[3233+1G>T]; [3139-1G>C] , versus unknown phases, e.g., c.[3233+1G>T(;)3139-1G>C]. Such assay is necessary for the cases with ambiguous clinical diagnosis and may become a part of routine procedure in the future, as technology progresses.
